EU sees 2025 pharma export uptick amid competitiveness concerns
New figures debuted by the European Union (EU) have uncovered a significant rise in the year-on-year value of pharma trade…
14 Apr 2026
Pharma 5.0, Sustainability & Security: PHARMAP 2026 brings pharma’s future into focus
As the pharmaceutical industry navigates a series of interconnected industry challenges, the pharma community's attention turns to Amsterdam. Later this month, major sector players gather for PHARMAP Congress 2026, scheduled…
14 Apr 2026
Travere Therapeutics gains FDA approval for sparsentan in FSGS
Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce proteinuria in adult and paediatric patients aged eight years and above with…
14 Apr 2026
Novo Nordisk and OpenAI forge alliance to drive speedy drug development
Novo Nordisk has partnered with tech giant OpenAI to expedite its drug development efforts, as the Danish pharma looks to fend off stiff competition from obesity market rival Eli Lilly.…
14 Apr 2026
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Merck & Co (MSD) and Daiichi Sankyo have received priority review from the US Food and Drug Administration (FDA) for ifinatamab deruxtecan’s biologics licence application (BLA) to treat extensive-stage small…
13 Apr 2026
AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid
AbbVie has cut a deal worth up to $745m with Chinese biopharmaceutical company, Haisco, to bolster its pain pipeline amid the company’s wider asset restocking efforts. Through this agreement, AbbVie…
13 Apr 2026
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies
Telix and Regeneron Pharmaceuticals have entered a partnership worth up to $4.3bn for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical…